Insider Transactions in Q2 2022 at Edwards Lifesciences Corp (EW)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 08
2022
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
13,256
+5.83%
|
-
|
|
May 08
2022
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,837
-12.86%
|
$683,700
$100.52 P/Share
|
|
May 08
2022
|
Bernard J Zovighian CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+19.16%
|
-
|
|
May 07
2022
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-1.12%
|
$13,400
$100.52 P/Share
|
|
May 07
2022
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
595
-1.93%
|
$59,500
$100.52 P/Share
|
|
May 07
2022
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
772
-2.98%
|
$77,200
$100.52 P/Share
|
|
May 07
2022
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
305
-1.62%
|
$30,500
$100.52 P/Share
|
|
May 07
2022
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
51
-0.03%
|
$5,100
$100.52 P/Share
|
|
May 07
2022
|
Huimin Wang CVP, Japan & Intercontinental |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-0.37%
|
$36,300
$100.52 P/Share
|
|
May 07
2022
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
604
-1.01%
|
$60,400
$100.52 P/Share
|
|
May 07
2022
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
679
-0.34%
|
$67,900
$100.52 P/Share
|
|
May 07
2022
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
633
-1.54%
|
$63,300
$100.52 P/Share
|
|
May 04
2022
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,037
+34.76%
|
-
|
|
May 04
2022
|
Martha H. Marsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+7.33%
|
-
|
|
May 04
2022
|
Heisz Leslie Stone Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+7.72%
|
-
|
|
May 04
2022
|
Huimin Wang CVP, Japan & Intercontinental |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-0.31%
|
$32,235
$105.93 P/Share
|
|
May 04
2022
|
Ramona Sequeira Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+31.88%
|
-
|
|
May 04
2022
|
Nicholas J Valeriani Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+3.36%
|
-
|
|
May 04
2022
|
Paul A Laviolette Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+31.88%
|
-
|
|
May 04
2022
|
Steven R Loranger Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,037
+2.81%
|
-
|
|
May 04
2022
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
567
-0.28%
|
$59,535
$105.93 P/Share
|
|
May 04
2022
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
496
-0.82%
|
$52,080
$105.93 P/Share
|
|
May 04
2022
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
42
-0.03%
|
$4,410
$105.93 P/Share
|
|
May 04
2022
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
279
-1.46%
|
$29,295
$105.93 P/Share
|
|
May 04
2022
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
441
-1.68%
|
$46,305
$105.93 P/Share
|
|
May 04
2022
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
116
-0.96%
|
$12,180
$105.93 P/Share
|
|
May 04
2022
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
23,400
-16.81%
|
$2,457,000
$105.05 P/Share
|
|
May 04
2022
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
493
-0.9%
|
$51,765
$105.93 P/Share
|
|
May 04
2022
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
23,400
+29.95%
|
$491,400
$21.76 P/Share
|
|
May 04
2022
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
370
-0.89%
|
$38,850
$105.93 P/Share
|
|
May 03
2022
|
Michael A Mussallem Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,250
+17.45%
|
-
|
|
May 03
2022
|
Larry L Wood Global President TAVR & Surg |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+2.14%
|
-
|
|
May 03
2022
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,775
+5.88%
|
-
|
|
May 03
2022
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
2,750
+1.74%
|
-
|
|
May 03
2022
|
Daveen Chopra CVP, TMTT |
BUY
Grant, award, or other acquisition
|
Direct |
3,250
+14.56%
|
-
|
|
May 03
2022
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+15.96%
|
-
|
|
May 03
2022
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
1,180
+8.92%
|
-
|
|
May 03
2022
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
3,775
+10.75%
|
-
|
|
May 03
2022
|
Bernard J Zovighian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,150
+9.08%
|
-
|
|
Apr 29
2022
|
Michael A Mussallem Director |
BUY
Bona fide gift
|
Indirect |
12,500
+0.37%
|
-
|
|
Apr 29
2022
|
Michael A Mussallem Director |
SELL
Bona fide gift
|
Direct |
12,500
-13.62%
|
-
|
|
Apr 29
2022
|
Michael A Mussallem Director |
SELL
Open market or private sale
|
Direct |
32,550
-5.82%
|
$3,482,850
$107.88 P/Share
|
|
Apr 29
2022
|
Michael A Mussallem Director |
BUY
Exercise of conversion of derivative security
|
Direct |
45,050
+26.6%
|
$946,050
$21.76 P/Share
|
|
Apr 28
2022
|
Martha H. Marsh Director |
SELL
Open market or private sale
|
Direct |
28,722
-51.75%
|
$3,101,976
$108.09 P/Share
|
|
Apr 28
2022
|
Martha H. Marsh Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,722
+34.1%
|
$718,050
$25.99 P/Share
|
|
Apr 11
2022
|
Catherine M. Szyman CVP, Critical Care |
SELL
Open market or private sale
|
Direct |
20,000
-16.27%
|
$2,440,000
$122.16 P/Share
|
|
Apr 11
2022
|
Catherine M. Szyman CVP, Critical Care |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+29.6%
|
$420,000
$21.76 P/Share
|
|
Apr 08
2022
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Open market or private sale
|
Direct |
11,660
-3.56%
|
$1,434,180
$123.43 P/Share
|
|
Apr 08
2022
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
11,660
+6.64%
|
$244,860
$21.76 P/Share
|
|
Apr 08
2022
|
Huimin Wang CVP, Japan & Intercontinental |
SELL
Open market or private sale
|
Direct |
3,675
-3.61%
|
$452,025
$123.07 P/Share
|